Item
8.01 Other Events.
American
Society of Gene Therapy Presentation
On
May
29, 2008, Mark Thornton, M.D., Ph.D., Senior Vice President of Product
Development of GenVec, Inc. (“GenVec”), delivered a presentation to the American
Society of Gene Therapy regarding
TNFerade™ clinical development, including an update on long-term survival data
from its Phase II clinical trial using TNFerade in patients with esophageal
cancer. A
copy of
the press release regarding Dr. Thorton’s presentation is attached to this
Current Report on Form 8-K as Exhibit 99.1 and is incorporated in this report
by
reference. A copy of Dr. Thornton’s presentation is attached to this Current
Report on Form 8-K as Exhibit 99.2 and is incorporated in this report by
reference.
American
Society for Clinical Oncology (ASCO)
On
May
31, 2008, GenVec issued a press release announcing a poster session at the
annual meeting of the American Society for Clinical Oncology (ASCO) by study
investigator Everett Vokes, M.D., University of Chicago. The poster presentation
by Dr. Vokes, entitled “A
phase
I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade) with concurrent
chemoradiotherapy in patients with recurrent head and neck cancer (HNC),”
reported study results. A copy of the press release is attached to this Current
Report on Form 8-K as Exhibit 99.3 and is incorporated in this report by
reference.
Statements
contained in the exhibits to this Current Report, including those relating
to
future performance, development, results or events and other matters, are
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act. GenVec cautions that these forward-looking statements
are
subject to numerous assumptions, risks and uncertainties, which change over
time. Factors that may cause actual results to differ materially from the
results discussed in the forward-looking statements or historical experience
include risks and uncertainties, including the failure by GenVec to secure
and
maintain relationships with collaborators; risks relating to certain of our
product candidates being in early stages of development; uncertainties relating
to clinical trials; risks relating to the commercialization, if any, of GenVec’s
proposed product candidates; dependence on the efforts of third parties;
dependence on intellectual property; and risks that we may lack the financial
resources and access to capital to fund our operations. Further information
on
the factors and risks that could affect GenVec’s future results are contained in
GenVec’s filings with the U.S. Securities and Exchange Commission (SEC), which
are available at www.sec.gov,
including in the risk factors section of GenVec’s Annual Report on Form 10-K.
These forward-looking statements speak only as of the date of the exhibits
to
this Current Report in which they appear, and GenVec assumes no duty to update
forward-looking statements.
Item
9.01 Financial Statements and Exhibits.
|
(d)
|
Exhibits
|
|
99.1
|
GenVec,
Inc. press release dated May 29, 2008.
|
|
99.2
|
GenVec,
Inc. presentation dated May 29, 2008.
|
|
99.3
|
GenVec,
Inc. press release dated May 31,
2008.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
GENVEC,
INC.
|
||
|
Date:
June 2, 2008
|
By:
|
/s/
Douglas J. Swirsky
|
|
Douglas
J. Swirsky
|
||
|
Senior Vice President, Chief Financial Officer,
Treasurer
and Corporate Secretary
|
||
EXHIBIT
INDEX
|
GenVec,
Inc. press release dated May 29, 2008.
|
|
|
99.2
|
GenVec,
Inc. presentation dated May 29, 2008.
|
|
99.3
|
GenVec,
Inc. press release dated May 31,
2008.
|